{"id":344692,"date":"2025-08-24T13:48:43","date_gmt":"2025-08-24T13:48:43","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-novartis-ag\/"},"modified":"2025-08-24T13:48:43","modified_gmt":"2025-08-24T13:48:43","slug":"how-to-buy-novartis-ag","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/","title":{"rendered":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Novartis AG (NVS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu ila\u00e7 devine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel hisse fiyat\u0131n\u0131, riskleri ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Novartis AG (NVS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu ila\u00e7 devine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel hisse fiyat\u0131n\u0131, riskleri ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Her g\u00fcn t\u0131bb\u0131 d\u00f6n\u00fc\u015ft\u00fcren d\u00fcnyan\u0131n en b\u00fcy\u00fck ila\u00e7 \u015firketlerinden birinin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Novartis AG, b\u00fcy\u00fcme ve savunma pozisyonu arayan yat\u0131r\u0131mc\u0131lar i\u00e7in istikrar, yenilik ve k\u00fcresel sa\u011fl\u0131k etkisini temsil ediyor. NVS hissesinin neden dikkatinizi hak etti\u011fini ve bu t\u0131bbi devrimin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Her g\u00fcn t\u0131bb\u0131 d\u00f6n\u00fc\u015ft\u00fcren d\u00fcnyan\u0131n en b\u00fcy\u00fck ila\u00e7 \u015firketlerinden birinin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Novartis AG, b\u00fcy\u00fcme ve savunma pozisyonu arayan yat\u0131r\u0131mc\u0131lar i\u00e7in istikrar, yenilik ve k\u00fcresel sa\u011fl\u0131k etkisini temsil ediyor. NVS hissesinin neden dikkatinizi hak etti\u011fini ve bu t\u0131bbi devrimin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Novartis Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla Novartis AG (NVS) <strong>126,98 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014\u015firketin sa\u011flam performans\u0131n\u0131 ve piyasa g\u00fcvenini yans\u0131tan g\u00fc\u00e7l\u00fc bir konum. Bu \u0130svi\u00e7reli ila\u00e7 devi sadece ba\u015fka bir hisse senedi de\u011fil; k\u00fcresel sa\u011fl\u0131k inovasyonunun temel ta\u015flar\u0131ndan biridir.<\/p> <p><strong>Takviminize Not Edin: 4 Kas\u0131m 2025<\/strong> bir sonraki kritik tarihiniz. Novartis'in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn ve tarihsel olarak bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketleri yarat\u0131r. \u015eirketin 17 Temmuz 2025'teki son kazan\u00e7lar\u0131, \u00e7ift haneli sat\u0131\u015f b\u00fcy\u00fcmesi ve temel marj geni\u015flemesi ile etkileyici sonu\u00e7lar g\u00f6sterdi.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 NVS Hissesini Nas\u0131l Etkiler?<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Fiyat Etkisi<\/th><th>S\u00fcre<\/th><\/tr> <\/thead> <tbody> <tr><td>17 Temmuz 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td><td>%3,2 Art\u0131\u015f<\/td><td>2 g\u00fcn<\/td><\/tr> <tr><td>22 Nisan 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>%2,1 Art\u0131\u015f<\/td><td>1 hafta<\/td><\/tr> <tr><td>5 \u015eubat 2025<\/td><td>Y\u0131ll\u0131k Rapor<\/td><td>%4,8 Art\u0131\u015f<\/td><td>3 g\u00fcn<\/td><\/tr> <tr><td>29 Ekim 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>%1,5 D\u00fc\u015f\u00fc\u015f<\/td><td>Ufak d\u00fc\u015f\u00fc\u015f<\/td><\/tr> <tr><td>18 Temmuz 2024<\/td><td>2. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>%3,6 Art\u0131\u015f<\/td><td>S\u00fcrekli b\u00fcy\u00fcme<\/td><\/tr> <tr><td>23 Nisan 2024<\/td><td>1. \u00c7eyrek Performans\u0131<\/td><td>%2,3 Art\u0131\u015f<\/td><td>\u0130stikrarl\u0131 y\u00fckseli\u015f<\/td><\/tr> <\/tbody> <\/table> <p>Model, Novartis'in genellikle g\u00fc\u00e7l\u00fc kazan\u00e7lar\u0131n ard\u0131ndan pozitif momentum ya\u015fad\u0131\u011f\u0131n\u0131, ara s\u0131ra ufak d\u00fczeltmelerin ise al\u0131m f\u0131rsatlar\u0131 sundu\u011funu g\u00f6steriyor.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ocak-A\u011fustos 2025<\/h2> <p>Novartis hisseleri son alt\u0131 ayda ola\u011fan\u00fcst\u00fc dayan\u0131kl\u0131l\u0131k ve b\u00fcy\u00fcme g\u00f6sterdi:<\/p> <ul> <li><strong>Ocak 2025<\/strong>: Yakla\u015f\u0131k 96,91 $ seviyesinden ba\u015flad\u0131, \u015firketin yeniden yap\u0131land\u0131rma faydalar\u0131n\u0131n fark edilmesiyle %7,61 artt\u0131<\/li> <li><strong>\u015eubat 2025<\/strong>: G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131 haberleriyle momentum devam etti, %4,13 b\u00fcy\u00fcyerek 113 $ y\u00fcksek seviyesine ula\u015ft\u0131<\/li> <li><strong>Mart 2025<\/strong>: Piyasa 1. \u00e7eyrek beklentilerini sindirirken istikrarl\u0131 %2,23 kazan\u00e7<\/li> <li><strong>Nisan 2025<\/strong>: Dalgal\u0131 d\u00f6nem (%1,80) ile 97,72 $-114,70 $ aras\u0131nda geni\u015f oynakl\u0131k<\/li> <li><strong>May\u0131s 2025<\/strong>: Pozitif klinik deneme sonu\u00e7lar\u0131 aras\u0131nda sa\u011flam %2,00 b\u00fcy\u00fcme<\/li> <li><strong>Haziran 2025<\/strong>: Sat\u0131n alma haberleri g\u00fcveni art\u0131rarak g\u00fc\u00e7l\u00fc %4,54 toparlanma<\/li> <li><strong>Temmuz 2025<\/strong>: G\u00fc\u00e7l\u00fc y\u00fckseli\u015f sonras\u0131 kar realizasyonu nedeniyle %3,62 ufak d\u00fczeltme<\/li> <li><strong>A\u011fustos 2025<\/strong>: Yat\u0131r\u0131mc\u0131 g\u00fcvenini g\u00f6stererek mevcut 126,98 $ seviyesine toparlanma<\/li> <\/ul> <p><strong>Toplam 6 ayl\u0131k kazan\u00e7: Yakla\u015f\u0131k %28<\/strong>\u2014bir\u00e7ok ila\u00e7 sekt\u00f6r\u00fcndeki rakibini geride b\u0131rakarak NVS'nin b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131 aras\u0131nda neden favori oldu\u011funu g\u00f6steriyor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firket performans\u0131na dayanarak beklenenler:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 129-135 $ (g\u00fc\u00e7l\u00fc tatil \u00e7eyre\u011fi ve \u00fcr\u00fcn hatt\u0131 geli\u015fmeleri) \u2192 <strong>AL<\/strong><\/li> <li><strong>2026 Hedefi<\/strong>: 140-150 $ (son sat\u0131n almalar\u0131n ba\u015far\u0131l\u0131 entegrasyonu)<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 160-180 $ (gen terapisi ve imm\u00fcnoloji alan\u0131nda hakimiyet)<\/li> <li><strong>2030 Vizyonu<\/strong>: 200+ $ (k\u00fcresel sa\u011fl\u0131k geni\u015flemesi ve ya\u015flanan n\u00fcfus trendleri)<\/li> <\/ul> <p>Analistler aras\u0131nda k\u0131sa vadeli patent endi\u015felerine ra\u011fmen genel g\u00f6r\u00fc\u015f olumlu. Novartis'in yenilik\u00e7i ila\u00e7lara stratejik odaklanmas\u0131 ve son ba\u015far\u0131l\u0131 klinik denemeleri, uzun vadeli s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcme i\u00e7in konumland\u0131r\u0131yor.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Patent S\u00fcrelerinin Dolmas\u0131<\/strong>: \u00c7eyrekte 2,36 milyar $ gelir getiren Entresto, yak\u0131nda jenerik rekabetle kar\u015f\u0131 kar\u015f\u0131ya (<a href=\"https:\/\/www.ainvest.com\/news\/novartis-growth-slow-patent-expirations-loom-2507\/\">AInvest Raporu<\/a>)<\/li> <li><strong>Reg\u00fclasyon Bask\u0131s\u0131<\/strong>: 2023'te 907 uyar\u0131 mektubu ile FDA incelemesi art\u0131yor (%12 art\u0131\u015f 2022'ye g\u00f6re)<\/li> <li><strong>Fiyatland\u0131rma Reformlar\u0131<\/strong>: ABD h\u00fck\u00fcmetinin ila\u00e7 fiyatland\u0131rma \u00f6nerilerinden %15-20 gelir etkisi olas\u0131l\u0131\u011f\u0131<\/li> <li><strong>Bor\u00e7 Seviyeleri<\/strong>: 0,53 bor\u00e7\/\u00f6zsermaye oran\u0131 dikkatli izleme gerektiriyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>G\u00fc\u00e7l\u00fc \u00dcr\u00fcn Hatt\u0131<\/strong>: Sj\u00f6gren hastal\u0131\u011f\u0131 ve ITP i\u00e7in ianalumab'\u0131n olumlu Faz 3 sonu\u00e7lar\u0131<\/li> <li><strong>Stratejik Sat\u0131n Alma<\/strong>: MikroRNA yeteneklerini g\u00fc\u00e7lendiren 1,7 milyar $ de\u011ferindeki Regulus Therapeutics anla\u015fmas\u0131 tamamland\u0131<\/li> <li><strong>Piyasa Liderli\u011fi<\/strong>: K\u00fcresel ila\u00e7 sat\u0131\u015flar\u0131nda 5. s\u0131rada, devasa Ar-Ge yat\u0131r\u0131m\u0131yla<\/li> <li><strong>Temett\u00fc \u0130stikrar\u0131<\/strong>: Piyasa dalgalanmalar\u0131nda gelir sa\u011flayan %3,53 verim<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 temsil etmeyen pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine d\u00fczenli sabit miktarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: Potansiyel giri\u015f noktalar\u0131 i\u00e7in 4 Kas\u0131m kazan\u00e7lar\u0131n\u0131 takip edin<\/li> <li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong>: \u0130la\u00e7 hisseleri sab\u0131r gerektirir\u2014bu h\u0131zl\u0131 bir kar f\u0131rsat\u0131 de\u011fildir<\/li> <\/ol> <p>Esprili bir bak\u0131\u015f: \"NVS ticareti yapmak ila\u00e7 almak gibidir\u2014bazen k\u0131sa vadede ac\u0131t\u0131r ama uzun vadede portf\u00f6y\u00fcn\u00fcz\u00fcn sa\u011fl\u0131\u011f\u0131 i\u00e7in iyidir!\"<\/p>  <h2>\u2705 Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NYSE listeli hisseler ve uluslararas\u0131 eri\u015fim sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir\u2014genellikle 1-2 g\u00fcn s\u00fcrer<\/td><\/tr> <tr><td>3<\/td><td>Fon Yat\u0131r\u0131n<\/td><td>Riske atmaya rahat oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile yolculu\u011funuzu ba\u015flatabilir<\/td><\/tr> <tr><td>4<\/td><td>\"NVS\" Aray\u0131n<\/td><td>Sadece \"Novartis\" de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Piyasa emirleri yerine giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Komisyon \u00fccretlerini kontrol edin\u2014i\u015flem de\u011ferinizin %1'inden az olmas\u0131na dikkat edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonunuzu \u0130zleyin<\/td><td>Fiyat uyar\u0131lar\u0131 kurun ve \u015firket haberlerini d\u00fczenli olarak takip edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in m\u00fckemmel<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong>: Tek belge ile KYC s\u00fcreci dakikalar i\u00e7inde tamamlan\u0131r<\/li> <li><strong>K\u00fcresel eri\u015fim<\/strong>: D\u00fcnyan\u0131n her yerinden ABD hisseleri ticareti yap\u0131n<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinde kapsaml\u0131 \u00f6\u011frenme materyalleri<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, yeni ba\u015flayanlar i\u00e7in hisse senedi piyasas\u0131na giri\u015f engelini azalt\u0131rken ciddi yat\u0131r\u0131mc\u0131lar i\u00e7in profesyonel ara\u00e7lar sunar.<\/p>  <h2>\ud83c\udf0d 2025'te Novartis: Sa\u011fl\u0131kta \u0130novasyon Lideri<\/h2> <p>Novartis, \u00e7e\u015fitlendirilmi\u015f bir ila\u00e7 devinden odaklanm\u0131\u015f bir yenilik g\u00fcc\u00fcne d\u00f6n\u00fc\u015ferek saf yenilik\u00e7i ila\u00e7 \u015firketi olarak hakimiyet kuruyor. \u015eirket, 2025'te d\u00fcnya \u00e7ap\u0131nda 296 milyon hastaya ula\u015f\u0131rken, kardiyovask\u00fcler-b\u00f6brek-metabolik hastal\u0131klar, imm\u00fcnoloji, sinirbilim ve onkoloji olmak \u00fczere d\u00f6rt temel tedavi alan\u0131na odaklanmaya devam ediyor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Novartis, 2023 sonlar\u0131nda Sandoz jenerik i\u015f birimini ay\u0131rarak daha yal\u0131n ve odaklanm\u0131\u015f bir \u015firket yaratt\u0131; \u015fimdi keskin gen terapisi ve radyoligand tedavi ara\u015ft\u0131rmalar\u0131na milyarlarca yat\u0131r\u0131m yap\u0131yor. Basel merkezleri, ciddi hastal\u0131klar\u0131n tedavisini ger\u00e7ekten de\u011fi\u015ftiren k\u00fcresel bir t\u0131bbi inovasyon merkezi haline geldi.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Novartis Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla Novartis AG (NVS) <strong>126,98 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014\u015firketin sa\u011flam performans\u0131n\u0131 ve piyasa g\u00fcvenini yans\u0131tan g\u00fc\u00e7l\u00fc bir konum. Bu \u0130svi\u00e7reli ila\u00e7 devi sadece ba\u015fka bir hisse senedi de\u011fil; k\u00fcresel sa\u011fl\u0131k inovasyonunun temel ta\u015flar\u0131ndan biridir.<\/p>\n<p><strong>Takviminize Not Edin: 4 Kas\u0131m 2025<\/strong> bir sonraki kritik tarihiniz. Novartis&#8217;in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn ve tarihsel olarak bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketleri yarat\u0131r. \u015eirketin 17 Temmuz 2025&#8217;teki son kazan\u00e7lar\u0131, \u00e7ift haneli sat\u0131\u015f b\u00fcy\u00fcmesi ve temel marj geni\u015flemesi ile etkileyici sonu\u00e7lar g\u00f6sterdi.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 NVS Hissesini Nas\u0131l Etkiler?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Fiyat Etkisi<\/th>\n<th>S\u00fcre<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>17 Temmuz 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td>\n<td>%3,2 Art\u0131\u015f<\/td>\n<td>2 g\u00fcn<\/td>\n<\/tr>\n<tr>\n<td>22 Nisan 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>%2,1 Art\u0131\u015f<\/td>\n<td>1 hafta<\/td>\n<\/tr>\n<tr>\n<td>5 \u015eubat 2025<\/td>\n<td>Y\u0131ll\u0131k Rapor<\/td>\n<td>%4,8 Art\u0131\u015f<\/td>\n<td>3 g\u00fcn<\/td>\n<\/tr>\n<tr>\n<td>29 Ekim 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>%1,5 D\u00fc\u015f\u00fc\u015f<\/td>\n<td>Ufak d\u00fc\u015f\u00fc\u015f<\/td>\n<\/tr>\n<tr>\n<td>18 Temmuz 2024<\/td>\n<td>2. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>%3,6 Art\u0131\u015f<\/td>\n<td>S\u00fcrekli b\u00fcy\u00fcme<\/td>\n<\/tr>\n<tr>\n<td>23 Nisan 2024<\/td>\n<td>1. \u00c7eyrek Performans\u0131<\/td>\n<td>%2,3 Art\u0131\u015f<\/td>\n<td>\u0130stikrarl\u0131 y\u00fckseli\u015f<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Model, Novartis&#8217;in genellikle g\u00fc\u00e7l\u00fc kazan\u00e7lar\u0131n ard\u0131ndan pozitif momentum ya\u015fad\u0131\u011f\u0131n\u0131, ara s\u0131ra ufak d\u00fczeltmelerin ise al\u0131m f\u0131rsatlar\u0131 sundu\u011funu g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ocak-A\u011fustos 2025<\/h2>\n<p>Novartis hisseleri son alt\u0131 ayda ola\u011fan\u00fcst\u00fc dayan\u0131kl\u0131l\u0131k ve b\u00fcy\u00fcme g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>Ocak 2025<\/strong>: Yakla\u015f\u0131k 96,91 $ seviyesinden ba\u015flad\u0131, \u015firketin yeniden yap\u0131land\u0131rma faydalar\u0131n\u0131n fark edilmesiyle %7,61 artt\u0131<\/li>\n<li><strong>\u015eubat 2025<\/strong>: G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131 haberleriyle momentum devam etti, %4,13 b\u00fcy\u00fcyerek 113 $ y\u00fcksek seviyesine ula\u015ft\u0131<\/li>\n<li><strong>Mart 2025<\/strong>: Piyasa 1. \u00e7eyrek beklentilerini sindirirken istikrarl\u0131 %2,23 kazan\u00e7<\/li>\n<li><strong>Nisan 2025<\/strong>: Dalgal\u0131 d\u00f6nem (%1,80) ile 97,72 $-114,70 $ aras\u0131nda geni\u015f oynakl\u0131k<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Pozitif klinik deneme sonu\u00e7lar\u0131 aras\u0131nda sa\u011flam %2,00 b\u00fcy\u00fcme<\/li>\n<li><strong>Haziran 2025<\/strong>: Sat\u0131n alma haberleri g\u00fcveni art\u0131rarak g\u00fc\u00e7l\u00fc %4,54 toparlanma<\/li>\n<li><strong>Temmuz 2025<\/strong>: G\u00fc\u00e7l\u00fc y\u00fckseli\u015f sonras\u0131 kar realizasyonu nedeniyle %3,62 ufak d\u00fczeltme<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Yat\u0131r\u0131mc\u0131 g\u00fcvenini g\u00f6stererek mevcut 126,98 $ seviyesine toparlanma<\/li>\n<\/ul>\n<p><strong>Toplam 6 ayl\u0131k kazan\u00e7: Yakla\u015f\u0131k %28<\/strong>\u2014bir\u00e7ok ila\u00e7 sekt\u00f6r\u00fcndeki rakibini geride b\u0131rakarak NVS&#8217;nin b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131 aras\u0131nda neden favori oldu\u011funu g\u00f6steriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firket performans\u0131na dayanarak beklenenler:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 129-135 $ (g\u00fc\u00e7l\u00fc tatil \u00e7eyre\u011fi ve \u00fcr\u00fcn hatt\u0131 geli\u015fmeleri) \u2192 <strong>AL<\/strong><\/li>\n<li><strong>2026 Hedefi<\/strong>: 140-150 $ (son sat\u0131n almalar\u0131n ba\u015far\u0131l\u0131 entegrasyonu)<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 160-180 $ (gen terapisi ve imm\u00fcnoloji alan\u0131nda hakimiyet)<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 200+ $ (k\u00fcresel sa\u011fl\u0131k geni\u015flemesi ve ya\u015flanan n\u00fcfus trendleri)<\/li>\n<\/ul>\n<p>Analistler aras\u0131nda k\u0131sa vadeli patent endi\u015felerine ra\u011fmen genel g\u00f6r\u00fc\u015f olumlu. Novartis&#8217;in yenilik\u00e7i ila\u00e7lara stratejik odaklanmas\u0131 ve son ba\u015far\u0131l\u0131 klinik denemeleri, uzun vadeli s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcme i\u00e7in konumland\u0131r\u0131yor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Patent S\u00fcrelerinin Dolmas\u0131<\/strong>: \u00c7eyrekte 2,36 milyar $ gelir getiren Entresto, yak\u0131nda jenerik rekabetle kar\u015f\u0131 kar\u015f\u0131ya (<a href=\"https:\/\/www.ainvest.com\/news\/novartis-growth-slow-patent-expirations-loom-2507\/\">AInvest Raporu<\/a>)<\/li>\n<li><strong>Reg\u00fclasyon Bask\u0131s\u0131<\/strong>: 2023&#8217;te 907 uyar\u0131 mektubu ile FDA incelemesi art\u0131yor (%12 art\u0131\u015f 2022&#8217;ye g\u00f6re)<\/li>\n<li><strong>Fiyatland\u0131rma Reformlar\u0131<\/strong>: ABD h\u00fck\u00fcmetinin ila\u00e7 fiyatland\u0131rma \u00f6nerilerinden %15-20 gelir etkisi olas\u0131l\u0131\u011f\u0131<\/li>\n<li><strong>Bor\u00e7 Seviyeleri<\/strong>: 0,53 bor\u00e7\/\u00f6zsermaye oran\u0131 dikkatli izleme gerektiriyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>G\u00fc\u00e7l\u00fc \u00dcr\u00fcn Hatt\u0131<\/strong>: Sj\u00f6gren hastal\u0131\u011f\u0131 ve ITP i\u00e7in ianalumab&#8217;\u0131n olumlu Faz 3 sonu\u00e7lar\u0131<\/li>\n<li><strong>Stratejik Sat\u0131n Alma<\/strong>: MikroRNA yeteneklerini g\u00fc\u00e7lendiren 1,7 milyar $ de\u011ferindeki Regulus Therapeutics anla\u015fmas\u0131 tamamland\u0131<\/li>\n<li><strong>Piyasa Liderli\u011fi<\/strong>: K\u00fcresel ila\u00e7 sat\u0131\u015flar\u0131nda 5. s\u0131rada, devasa Ar-Ge yat\u0131r\u0131m\u0131yla<\/li>\n<li><strong>Temett\u00fc \u0130stikrar\u0131<\/strong>: Piyasa dalgalanmalar\u0131nda gelir sa\u011flayan %3,53 verim<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 temsil etmeyen pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine d\u00fczenli sabit miktarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: Potansiyel giri\u015f noktalar\u0131 i\u00e7in 4 Kas\u0131m kazan\u00e7lar\u0131n\u0131 takip edin<\/li>\n<li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong>: \u0130la\u00e7 hisseleri sab\u0131r gerektirir\u2014bu h\u0131zl\u0131 bir kar f\u0131rsat\u0131 de\u011fildir<\/li>\n<\/ol>\n<p>Esprili bir bak\u0131\u015f: &#8220;NVS ticareti yapmak ila\u00e7 almak gibidir\u2014bazen k\u0131sa vadede ac\u0131t\u0131r ama uzun vadede portf\u00f6y\u00fcn\u00fcz\u00fcn sa\u011fl\u0131\u011f\u0131 i\u00e7in iyidir!&#8221;<\/p>\n<h2>\u2705 Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NYSE listeli hisseler ve uluslararas\u0131 eri\u015fim sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir\u2014genellikle 1-2 g\u00fcn s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon Yat\u0131r\u0131n<\/td>\n<td>Riske atmaya rahat oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile yolculu\u011funuzu ba\u015flatabilir<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;NVS&#8221; Aray\u0131n<\/td>\n<td>Sadece &#8220;Novartis&#8221; de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Piyasa emirleri yerine giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014i\u015flem de\u011ferinizin %1&#8217;inden az olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonunuzu \u0130zleyin<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun ve \u015firket haberlerini d\u00fczenli olarak takip edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in m\u00fckemmel<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong>: Tek belge ile KYC s\u00fcreci dakikalar i\u00e7inde tamamlan\u0131r<\/li>\n<li><strong>K\u00fcresel eri\u015fim<\/strong>: D\u00fcnyan\u0131n her yerinden ABD hisseleri ticareti yap\u0131n<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinde kapsaml\u0131 \u00f6\u011frenme materyalleri<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, yeni ba\u015flayanlar i\u00e7in hisse senedi piyasas\u0131na giri\u015f engelini azalt\u0131rken ciddi yat\u0131r\u0131mc\u0131lar i\u00e7in profesyonel ara\u00e7lar sunar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Novartis: Sa\u011fl\u0131kta \u0130novasyon Lideri<\/h2>\n<p>Novartis, \u00e7e\u015fitlendirilmi\u015f bir ila\u00e7 devinden odaklanm\u0131\u015f bir yenilik g\u00fcc\u00fcne d\u00f6n\u00fc\u015ferek saf yenilik\u00e7i ila\u00e7 \u015firketi olarak hakimiyet kuruyor. \u015eirket, 2025&#8217;te d\u00fcnya \u00e7ap\u0131nda 296 milyon hastaya ula\u015f\u0131rken, kardiyovask\u00fcler-b\u00f6brek-metabolik hastal\u0131klar, imm\u00fcnoloji, sinirbilim ve onkoloji olmak \u00fczere d\u00f6rt temel tedavi alan\u0131na odaklanmaya devam ediyor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Novartis, 2023 sonlar\u0131nda Sandoz jenerik i\u015f birimini ay\u0131rarak daha yal\u0131n ve odaklanm\u0131\u015f bir \u015firket yaratt\u0131; \u015fimdi keskin gen terapisi ve radyoligand tedavi ara\u015ft\u0131rmalar\u0131na milyarlarca yat\u0131r\u0131m yap\u0131yor. Basel merkezleri, ciddi hastal\u0131klar\u0131n tedavisini ger\u00e7ekten de\u011fi\u015ftiren k\u00fcresel bir t\u0131bbi inovasyon merkezi haline geldi.<\/p>\n"},"faq":[{"question":"Novartis hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"NVS\" sembol\u00fcn\u00fc aray\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in, i\u015flemi onaylay\u0131n ve pozisyonunuzu izleyin."},{"question":"Novartis hisselerinin riskleri nelerdir?","answer":"Patent s\u00fcrelerinin dolmas\u0131, reg\u00fclasyon bask\u0131s\u0131, fiyatland\u0131rma reformlar\u0131 ve bor\u00e7 seviyeleri temel riskler aras\u0131ndad\u0131r."},{"question":"Novartis hisseleri i\u00e7in fiyat tahmini nedir?","answer":"2025 sonunda 129-135 $, 2026'da 140-150 $, 2028'de 160-180 $ ve 2030'da 200+ $ olarak \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, fiyat uyar\u0131lar\u0131 kurun ve uzun vadeli d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, k\u00fcresel eri\u015fim ve kapsaml\u0131 e\u011fitim kaynaklar\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Novartis hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"NVS\" sembol\u00fcn\u00fc aray\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in, i\u015flemi onaylay\u0131n ve pozisyonunuzu izleyin."},{"question":"Novartis hisselerinin riskleri nelerdir?","answer":"Patent s\u00fcrelerinin dolmas\u0131, reg\u00fclasyon bask\u0131s\u0131, fiyatland\u0131rma reformlar\u0131 ve bor\u00e7 seviyeleri temel riskler aras\u0131ndad\u0131r."},{"question":"Novartis hisseleri i\u00e7in fiyat tahmini nedir?","answer":"2025 sonunda 129-135 $, 2026'da 140-150 $, 2028'de 160-180 $ ve 2030'da 200+ $ olarak \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, fiyat uyar\u0131lar\u0131 kurun ve uzun vadeli d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, k\u00fcresel eri\u015fim ve kapsaml\u0131 e\u011fitim kaynaklar\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T13:48:43+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T13:48:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\",\"name\":\"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-24T13:48:43+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/","og_locale":"tr_TR","og_type":"article","og_title":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T13:48:43+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T13:48:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/","name":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-24T13:48:43+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novartis-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Novartis AG (NVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Novartis AG (NVS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":344694,"slug":"how-to-buy-novartis-ag","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Novartis AG (NVS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Novartis AG (NVS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-novartis-ag\/"},"pt_AA":{"locale":"pt_AA","id":344690,"slug":"how-to-buy-novartis-ag","post_title":"Como comprar a\u00e7\u00f5es da Novartis AG (NVS) - Investimento em a\u00e7\u00f5es da Novartis AG (NVS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-novartis-ag\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=344692"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344692\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=344692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=344692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=344692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}